Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of I omega kids®/Pufan 3 kids® on serenity (Question No EFSA-Q-2008-092 and Question No EFSA-Q-2008-097) [The EFSA Journal (2008) 831, 1-2.]. The claim proposed by the applicant was worded as follows: ‘provide serenity and room for a beneficial development of the child’.
Recital 39, Commission Regulation (EC) No 983/2009 of 21 October 2009 on the authorisation and refus…
In forcesince 21 Oct 2009